{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:50:33Z","timestamp":1791215433850,"version":"4.1.0"},"reference-count":64,"publisher":"Wiley","issue":"24","license":[{"start":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T00:00:00Z","timestamp":1766275200000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The KRAS G12D mutation is a highly prevalent oncogenic driver in pancreatic ductal adenocarcinoma, colorectal cancer, and non\u2010small cell lung cancer. Unlike other KRAS variants, G12D lacks a reactive site; therefore, it is considered \u201cundruggable\u201d and exhibits a propensity to activate the PI3K\/AKT pathway while fostering an immunosuppressive microenvironment. This review summarizes recent breakthroughs in inhibitor design that are reshaping the therapeutic landscape for KRAS G12D. Significant progress has been made in the development of small\u2010molecule inhibitors: non\u2010covalent inhibitors (e.g., MRTX1133) exploit ionic interactions (salt bridges) with the mutant aspartic acid residue to achieve high affinity and selectivity; novel covalent strategies are emerging, including strain\u2010release alkylation and tri\u2010complex inhibitors (e.g., RMC\u20109805). Alternative modalities such as Proteolysis Targeting Chimeras (PROTACs), peptide inhibitors, and monobodies are also discussed. The article further evaluates the status of candidate drugs currently in clinical trials and addresses the critical challenges of acquired resistance, which may arise through secondary mutations or bypass signaling pathways. Finally, it emphasizes future directions, including the optimization of drug delivery via nanoparticles and the implementation of combination therapies to enhance efficacy and achieve durable clinical responses.<\/jats:p>","DOI":"10.1111\/1759-7714.70203","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T05:20:23Z","timestamp":1766380823000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Targeting\n                    <scp>KRAS G12D<\/scp>\n                    : Advances in Inhibitor Design"],"prefix":"10.1111","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8733-2789","authenticated-orcid":false,"given":"Kaiyin","family":"Shi","sequence":"first","affiliation":[{"name":"Beijing National Day School  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4695-3232","authenticated-orcid":false,"given":"Amin","family":"Li","sequence":"additional","affiliation":[{"name":"Jacobio Pharmaceuticals Group Co., Ltd.  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,21]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/2041104a0"},{"issue":"2","key":"e_1_2_10_3_1","first-page":"311","article-title":"Morphologic Responses to a Murine Erythroblastosis Virus","volume":"39","author":"Kirsten W. H.","year":"1967","journal-title":"Journal of the National Cancer Institute"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.16.4848"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj2790609"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201008\u20100646"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.277.5324.333"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/349117a0"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2821624"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.6695174"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392\u2010021\u201000780\u20104"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12796"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010019\u20101694\u20101"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917239"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01688"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.CD\u201020\u20100142"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2017.08.006"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41421\u2010021\u201000368\u2010w"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541\u20107786.MCR\u201015\u20100203"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.CD\u201019\u20101006"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1013902"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.CD\u201020\u20100442"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02752"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.MCT\u201020\u20100465"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555\u2010025\u201010243\u20109"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943\u2010024\u201002157\u2010x"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.TARG\u201023\u2010A085"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573\u2010021\u201000371\u20106"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010021\u201022125\u2010z"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0969\u20102126(00)80061\u20100"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194933"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1039\/d1sc03484g"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.2c05377"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41589\u2010024\u201001554\u20107"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1904529116"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1918164117"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114243"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1094887"},{"key":"e_1_2_10_39_1","unstructured":"ClinicalTrials.gov \u201cA Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation \u201dIdentifier: NCT06179160 2025 accessed July 21 2025 https:\/\/clinicaltrials.gov\/study\/NCT06179160."},{"key":"e_1_2_10_40_1","unstructured":"ClinicalTrials.gov \u201cA Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors \u201dIdentifier: NCT06403735 2025 accessed July 21 2025 https:\/\/clinicaltrials.gov\/study\/NCT06403735."},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1013902"},{"key":"e_1_2_10_42_1","unstructured":"\u201cVerastem Oncology Announces Updated Data from Partner Genfleet Therapeutics' Phase 1\/2 Trial of GFH375 (VS\u20107375) \u201dPresented at 2025 ASCO Annual Meeting. Verastem Investor Relations 2025 https:\/\/investor.verastem.com\/news\u2010releases\/news\u2010release\u2010details\/verastem\u2010oncology\u2010announces\u2010updated\u2010data\u2010partner\u2010genfleet."},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.3013"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.AM2025\u2010ND11"},{"key":"e_1_2_10_45_1","unstructured":"ClinicalTrials.gov \u201cA Phase I\/IIa Study to Investigate the Safety Tolerability Pharmacokinetics and Efficacy of AZD0022 as Monotherapy and in Combination With Anti\u2010Cancer Agents in Participants With Locally Advanced or Metastatic Solid Tumours With KRASG12D Mutation \u201dIdentifier: NCT06599502 2025 accessed July 21 2025 https:\/\/clinicaltrials.gov\/study\/NCT06599502."},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.4_suppl.TPS845"},{"key":"e_1_2_10_47_1","unstructured":"ClinicalTrials.gov \u201cMOONRAY\u201001 A Study of LY3962673 in Participants With KRAS G12D\u2010Mutant Solid Tumors \u201dIdentifier: NCT06586515 2025 accessed July 21 2025 https:\/\/clinicaltrials.gov\/study\/NCT06586515."},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164\u2010025\u201000637\u20104"},{"key":"e_1_2_10_49_1","unstructured":"ClinicalTrials.gov \u201cA Study of HRS\u20104642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation \u201dIdentifier: NCT05533463 2022 accessed July 21 2025 https:\/\/clinicaltrials.gov\/study\/NCT05533463."},{"key":"e_1_2_10_50_1","unstructured":"A.Hippensteele \u201cAACR 2025: Oral Investigational Agent Zoldonrasib Elicits Objective Responses in Patients With KRAS G12D\u2010Mutated NSCLC \u201dPharmacy Times 2025 https:\/\/www.pharmacytimes.com\/view\/oral\u2010investigational\u2010agent\u2010zoldonrasib\u2010elicits\u2010objective\u2010responses\u2010in\u2010patients\u2010with\u2010kras\u2010g12d\u2010mutated\u2010nsclc."},{"key":"e_1_2_10_51_1","unstructured":"\u201cAstellas Presents New Data that Explores Potential of its Cancer Therapies at 2025 ASCO Annual Meeting \u201dAstellas Newsroom 2025 https:\/\/newsroom.astellas.us\/2025\u201005\u201019\u2010Astellas\u2010Presents\u2010New\u2010Data\u2010that\u2010Explores\u2010Potential\u2010of\u2010its\u2010Cancer\u2010Therapies\u2010at\u20102025\u2010ASCO\u2010Annual\u2010Meeting."},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41589\u2010022\u201001065\u20109"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.2c02373"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010022\u201012401\u20103"},{"key":"e_1_2_10_55_1","unstructured":"\u201cAlice (688578.SH): AST2169 Approved to Conduct Clinical Trials for Advanced Solid Tumors With KRAS G12D Mutations \u201dWebull News 2024 https:\/\/www.webull.com\/news\/10395483944936448."},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.CAN\u201022\u20101278"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.0c00411"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2302485120"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105281"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010151"},{"key":"e_1_2_10_61_1","unstructured":"ClinicalTrials.gov \u201cStudy of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation \u201dIdentifier: NCT05737706 2025 accessed August 18 2025 https:\/\/clinicaltrials.gov\/study\/NCT05737706."},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00334-z"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.08.006"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201002903\u20100"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102309"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.70203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T09:54:12Z","timestamp":1766483652000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.70203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":64,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/1759-7714.70203"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.70203","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70203"}}